Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433.
复制标题
DOI：
10.1021/acs.chemrev.8b00211
复制
发表时间：
2019-01-23
期刊：
影响因子：
62.1
通讯作者：
McFarland SA
中科院分区：
文献类型：
--
作者：
Monro S;Colón KL;Yin H;Roque J 3rd;Konda P;Gujar S;Thummel RP;Lilge L;Cameron CG;McFarland SA
过渡金属配合物作为光敏剂在光动力疗法（PDT）和最近的光化学疗法（PCT）中越来越受到关注。近年来，Ru （II）多吡啶配合物已成为PDT和PCT研究最广泛的体系，其丰富的光化学和光物理性质来源于可见光和近红外光下可获得的各种激发态电子构型，这些性质可用于能量和电子转移过程，从而产生高效的氧依赖性和/或氧非依赖性光生物活性。所选的例子强调了在配位化学中合理设计的使用，以控制最低能量的三重态激发态配置，从而引发PDT和/或PCT效应的特定类型的光反应性。这些原则也在TLD1433的开发背景下进行了讨论，TLD1433是第一个进入人体临床试验的基于Ru（II）的PDT光敏剂。TLD1433的设计源于以肿瘤为中心的方法，作为完整PDT包的一部分，包括轻型组件和治疗非肌肉浸润性膀胱癌的方案。简要地说，这篇综述总结了将PDT纳入主流癌症治疗的挑战。它考虑了过渡金属配合物提供的化学和光物理解决方案，并将将新药引入临床试验所需的多学科努力纳入背景。
Transition metal complexes are of increasing interest as photosensitizers in photodynamic therapy (PDT) and, more recently, for photochemotherapy (PCT). In recent years, Ru (II) polypyridyl complexes have emerged as the most widely studied systems for both PDT and PCT. Their rich photochemical and photophysical properties derive from a variety of excited-state electronic configurations accessible with visible and near-infrared light, and these properties can be exploited for both energy- and electron-transfer processes that can yield highly potent oxygen-dependent and/or oxygen-independent photobiological activity. Selected examples highlight the use of rational design in coordination chemistry to control the lowest-energy triplet excited state configurations for eliciting a particular type of photoreactivity for PDT and/or PCT effects. These principles are also discussed in the context of the development of TLD1433, the first Ru(II)-based photosensitizer for PDT to enter a human clinical trial. The design of TLD1433 arose from a tumor-centered approach, as part of a complete PDT package that included the light component and the protocol for treating nonmuscle invasive bladder cancer. Briefly, this review summarizes the challenges to bringing PDT into mainstream cancer therapy. It considers the chemical and photophysical solutions that transition metal complexes offer, and it puts into context the multidisciplinary effort needed to bring a new drug to clinical trial.
登录
查看更多内容
DOI：
10.3322/caac.20114
发表时间：
2011-07
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Agostinis P;Berg K;Cengel KA;Foster TH;Girotti AW;Gollnick SO;Hahn SM;Hamblin MR;Juzeniene A;Kessel D;Korbelik M;Moan J;Mroz P;Nowis D;Piette J;Wilson BC;Golab J
通讯作者：
Golab J
DOI：
10.1016/j.jphotobiol.2010.06.004
发表时间：
2010-09-02
影响因子：
5.4
作者：
Berlanda, Juergen;Kiesslich, Tobias;Plaetzer, Kristjan
通讯作者：
Plaetzer, Kristjan
影响因子：
3.3
作者：
Allison, Ron R.
通讯作者：
Allison, Ron R.
影响因子：
15
作者：
Chakrabortty S;Agrawalla BK;Stumper A;Vegi NM;Fischer S;Reichardt C;Kögler M;Dietzek B;Feuring-Buske M;Buske C;Rau S;Weil T
通讯作者：
Weil T
DOI：
10.1039/c4pp00455h
发表时间：
2015-08
期刊：
Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
影响因子：
--
作者：
Anzengruber F;Avci P;de Freitas LF;Hamblin MR
通讯作者：
Hamblin MR